Thyroid Eye Disease: Multidisciplinary Management of Treatment-Associated Hearing Loss (Online CME Monograph)

Activity Description and Purpose

This educational activity is intended to help clinicians evaluate real-world data pertaining to hearing dysfunction associated with thyroid eye disease treatment with the insulin-like growth factor 1 receptor antagonist teprotumumab. Clinicians will learn how to implement optimal strategies for monitoring and managing hearing loss in patients treated with teprotumumab. The desired results of this activity are for clinicians to use a multidisciplinary approach to increase their ability to identify and manage hearing loss in patients who require treatment of thyroid eye disease.

Target Audience

This educational activity is intended for ophthalmologists, oculoplastic surgeons, and neuro-ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Evaluate key and impactful real-world data pertaining to hearing dysfunction associated with thyroid eye disease treatment
  • Implement optimal strategies for monitoring and managing hearing loss in patients treated with insulin-like growth factor 1 receptor antagonists for thyroid eye disease
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
12/31/2023
Course expires: 
12/31/2024

Faculty

Prem S. Subramanian, MD, PhD (Chair)
Chief, Neuro-Ophthalmology
Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology
Vice Chair for Academic Affairs, Ophthalmology
Professor in Ophthalmology, Neurology, and Neurosurgery
Sue Anschutz-Rodgers University of Colorado Eye Center
University of Colorado School of Medicine
Aurora, Colorado

Jennifer Alyono, MD, MS
Clinical Assistant Professor, Otolaryngology (Head and Neck Surgery)
Stanford Medicine
Stanford, California

César A. Briceño, MD
Associate Professor of Clinical Ophthalmology
Associate Professor of Ophthalmology in Dermatology
Scheie Eye Institute
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.

Faculty

Jennifer Alyono, MD, MS, is a contracted researcher for Astellas Pharma US, Inc,* and Cochlear Ltd.

César A. Briceño, MD, is an advisory board member of Amgen Inc, F. Hoffmann-La Roche Ltd, and Genentech, Inc.

Prem S. Subramanian, MD, PhD, is a consultant for Acelyrin, Inc; is an advisory board member of Amgen, GenSight Biologics, Kriya Therapeutics, and Viridian Therapeutics, Inc; and is a contracted researcher for Immunovant, Inc, Invex Therapeutics*, Neurophth Therapeutics, and Tourmaline Bio, Inc.

Peer Reviewer

Hadi Kaakour, MD, was formerly an advisory board member of Alimera Sciences*.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

* The financial relationship existed during the past 24 months but has now ended

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Amgen Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Amgen Inc.

This CME activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 308

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CME information for this activity.